Clinical, Epidemiological and Histopathological Aspects in Patients with Hepatocellular Carcinoma Undergoing Liver Transplantation
Overview
Authors
Affiliations
Background: Hepatocellular Carcinoma (HCC) is the primary liver cancer with high incidence and mortality rates. Currently one of the major etiologies for liver disease, HCC and liver transplantation is nonalcoholic fatty liver disease (NAFLD). The aim of the present study was to evaluate the epidemiological, histopathological and clinical aspects of HCC transplant patients, with emphasis on NAFLD etiology. Methods: This study included all HCC patients submitted to liver transplantation from 2010 to 2016 of the University Reference Center. The analyzed variables were age, gender, ethnicity, causes that led to liver transplantation, alpha-fetoprotein (AFP) dosage, histological aspects, recurrence, survival and NAFLD. Results: A total of 60 patients were included in the study being 80% men with a mean age of 58.3 ± 10.6 years. All patients were cirrhotic. The causes that led to the transplantation were the presence of the hepatitis C virus (HCV) (56.6% of the patients), an association of the virus with alcohol (20%), the presence of the hepatitis B virus (HBV) (20%), alcoholic liver disease (ALD) (50.9%) and NAFLD (25%). Of the latter, eight were diagnosed pre-transplantation and seven were NAFLD carriers without a previous diagnosis. Regarding the Edmondson-Steiner histological classification, 58.5% of the patients were classified as grade ≤ II. Conclusions: There is predominance of male patients with a mean age of 58.3 years. Degree ≤ II is the most frequent to the Edmondson-Steiner histological classification in the evaluated casuistic. HCV, ALD and NAFLD is the most common etiological agents found in the study. The (high) underestimated prevalence of NAFLD in the pre-transplanted patients is due to the fact that all patients presented cirrhosis, masking NAFLD signals.
Time trends and geographic distribution of hepatocellular carcinoma in Brazil: An ecological study.
Balbi E, Moreira J, Luiz R, Perez R, de Souza H Medicine (Baltimore). 2022; 101(38):e30614.
PMID: 36197232 PMC: 9509041. DOI: 10.1097/MD.0000000000030614.
Chen Y, Huang M, Zhu J, Xu L, Cheng W, Lu X Front Pharmacol. 2022; 13:857060.
PMID: 35496321 PMC: 9038539. DOI: 10.3389/fphar.2022.857060.
Murtha-Lemekhova A, Fuchs J, Schulz E, Sterkenburg A, Mayer P, Pfeiffenberger J J Hepatocell Carcinoma. 2021; 8:1269-1279.
PMID: 34712626 PMC: 8547765. DOI: 10.2147/JHC.S328198.
Identification and Validation of Key Genes in Hepatocellular Carcinoma by Bioinformatics Analysis.
Wang J, Peng R, Zhang Z, Zhang Y, Dai Y, Sun Y Biomed Res Int. 2021; 2021:6662114.
PMID: 33688500 PMC: 7925030. DOI: 10.1155/2021/6662114.
Cao T, Yi S, Wang L, Zhao J, Xiao J, Xie N Biomed Res Int. 2020; 2020:3574261.
PMID: 32964028 PMC: 7499325. DOI: 10.1155/2020/3574261.